Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment
Intrapatient ctDNA variability over time in <i>EGFR-</i>mutant advanced NSCLC includes changes that may confound interpretation of treatment activity, depending on the magnitude of change used to indicate molecular response. These findings demonstrate that evaluation of on-treatment changes must account for potential background variability, including technical variability because of factors such as cfDNA input level and tumor-related VAF, and that baseline samples should be obtained as close as possible to treatment initiation to minimize the impact of background variability.
Authors
- Diana Merino Vega (ORCID: https://orcid.org/0000-0002-6173-6957)
- Katie Quinn (ORCID: https://orcid.org/0009-0006-6905-2257)
- J. Carl Barrett (ORCID: https://orcid.org/0000-0003-4042-9859)
- Ryan J. Hartmaier (ORCID: https://orcid.org/0000-0001-7416-6036)
- Aleksandra Markovets (ORCID: https://orcid.org/0000-0003-0957-0424)
- Kyle Chang (ORCID: https://orcid.org/0000-0001-5295-9676)
- Sara Wienke (ORCID: https://orcid.org/0009-0005-7630-2210)
- Darren Hodgson (ORCID: https://orcid.org/0000-0002-6631-9626)
- Chris Abbosh
Institutions
- Guardant (United States) (US)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Finland) (FI)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/po-25-00287
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00